藥盒灌注巖舒針聯(lián)合TACE治療中晚期肝癌的臨床觀察.pdf

1、廣州中醫(yī)藥大學(xué)碩士學(xué)位論文藥盒灌注巖舒針聯(lián)合TACE治療中晚期肝癌的臨床觀察姓名：吳錦燕申請學(xué)位級別：碩士專業(yè)：中醫(yī)腫瘤學(xué)指導(dǎo)教師：徐凱20070401CIinicalobservationofCompIexSophoraeInjectiOl3CombiningwithInterventionaItherapyonTreatingLiverCancerAbstractSpeciaIity：PhymatologyOfChinesemedc

2、alscienceAuthor：WuJinYanTutor：XuKaiPart1westudiedtheknowledgeofModernMedicineandTraditionalChineseMedicine(TCM)totheinterventionaltherapyforPrimaryLivercancerAndWediscussedthebasicandsignificanceoftheresearchPartIIclinic

3、alstudyObjective：ToobsevetheclinicalefficacyoftheanticancerChinesetraditionalmedicine，anddiscussthefeasibilityandadvantageoftheanticancerChinesetraditionalmedicineMethods：62patientswithstageII—IIIlivercancerwerebroughtin

4、tothisreserchTheywererandomlydividedintotreatinggroup(32patients)andconctrolgroup(30patients)ThetherapywaseverygroupsallmademedcinboxunderskinandaffusedHCPTIOmg、THP20mgthroughthehepaticatery，If，addiodizedoil510mgAfter7da

5、ystreatinggroupwasaffusingComplexSophoraeInjection20mlthroughthehepaticatery，qd，21daysonceNextfivedaysthetwogroupsallwereaffusingHCPTIOmg，THP20mgthroughthehepaticaterychemotherapyanothers。Thetwogroupsallwereaffusing3time

6、schemotherapythroughthehepaticaterychemotherapyTocomparethevolumeoftumor，thesideeffectaftertherapy，thefunctionof1iver，KPSandavoirdupoisResult：accordingtoeffectivepower，thereisondistinguishstatisticalsignificancebetweenaf

7、fusionthroughthehepaticaterywithComplexSophoraeInjectioncombinedwithTACEandTACE(PO05)，buttreatinggroupishigherthancontrolgroupintumorstableratio(PO01)，whileshowsnodistinguishstatisticalsignificanceinsurvivalratethereisno

8、distinguishstatisticalsignificanceinthedigestiveresponseincidencerate(PO05)，butthereisinthefever，paininliverandleukocyte(P005PO05)accordingtocarnofskyscore，thereisnodistinguishstatisticalsignificancebetweentwogroupsafter